Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K δ/γ Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects

Silvia Laura Locatelli, PhD, Francesca Maria Consonni, Giuseppa Careddu, Simone Serio, Srikant Viswanadha, PhD, Swaroop Vakkalanka, PhD, Luca Castagna, MD, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2016) 128 (22): 45.

https://doi.org/10.1182/blood.V128.22.45.45

Published: 2016

Journal Articles

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

Owen A. O'Connor, MD, Ian W. Flinn, MD PhD, Manish R. Patel, MD, Timothy S. Fenske, MD, Changchun Deng, MD PhD, Danielle M. Brander, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John G Kuhn, Pharm.D., Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Howard A. Burris, III, MD

Blood (2015) 126 (23): 4154.

https://doi.org/10.1182/blood.V126.23.4154.4154

Published: 2015

Journal Articles

A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

Carmelo Carlo-Stella, MD, Richard Delarue, MD, Prajak J Barde, MD, Lydia Scarfo, Thamila Saheb, Uday Kumar, Srikant Viswanadha, PhD, Sara Gandolfi, MD, Valeria Pittari, MD, Armando Santoro, MD, Silvia Laura Locatelli, PhD, Swaroop Vakkalanka, PhD, Paolo Ghia, MD PhD, Andres J.M. Ferreri

Blood (2015) 126 (23): 1495.

https://doi.org/10.1182/blood.V126.23.1495.1495

Published: 2015

Journal Articles

Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis

Silvia Laura Locatelli, PhD, Giuseppa Careddu, Armando Chierchia, Srikant Viswanadha, PhD, Swaroop Vakkalanka, PhD, Luca Castagna, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2015) 126 (23): 1561.

https://doi.org/10.1182/blood.V126.23.1561.1561

Published: 2015

Journal Articles

The PI3K-δ Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

Silvia L Locatelli, PhD, Silvia Tartari, PhD, Luca Castagna, MD, Rita Mazza, Srikant Viswanadha, PhD, Peter Sportelli, Swaroop Vakkalanka, PhD, Armando Santoro, MD, Carmelo Carlo-Stella, MD

Blood (2014) 124 (21): 4486.

https://doi.org/10.1182/blood.V124.21.4486.4486

Published: 2014

Journal Articles

Addition of RP6530, a Dual PI3Kδ/γ Inhibitor, Overcomes Ibrutinib Resistance in DLBCL Cells in Vitro

Swaroop Vakkalanka, PhD, Seeta Nyayapathy, M.S., Srikant Viswanadha, PhD

Blood (2014) 124 (21): 4497.

https://doi.org/10.1182/blood.V124.21.4497.4497

Published: 2014

Journal Articles

A Phase I Dose Escalation Study of RP6530, a Novel, Dual PI3K-γδ Inhibitor, for Patients with Relapsed or Refractory Hematologic Malignancies

Lydia Scarfò, Prajak J Barde, MBBS, MD, Claudia Fazi, PhD, Uday Kumar, Srikant Viswanadha, PhD, Swaroop Vakkalanka, PhD, Paolo Ghia, MD, Andres J.M. Ferreri, MD PhD

Blood (2014) 124 (21): 3043.

https://doi.org/10.1182/blood.V124.21.3043.3043

Published: 2014

Journal Articles

Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma

Matthew A. Lunning, DO, Julie M. Vose, MD MBA, Marshall T. Schreeder, MD, Nathan Fowler, MD, Loretta J. Nastoupil, MD, Tanya Siddiqi, MD, Susan Blumel, RN, BSN, Emily K. Pauli, BMBS, PharmD, Kathy Cutter, RN, BSN, Warner Tse, RN, Hari P. Miskin, MS, Peter Sportelli, Michael S. Weiss, Swaroop Vakkalanka, PhD, Srikant Viswanadha, PhD, Susan O'Brien, MD

Blood (2014) 124 (21): 801.

https://doi.org/10.1182/blood.V124.21.801.801

Published: 2014

Journal Articles

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Howard A. Burris, MD, Manish R. Patel, MD, Danielle M. Brander, MD, Owen A. O'Connor, MD PhD, Changchun Deng, MD PhD, Timothy S. Fenske, MD, Martin Gutierrez, MD, Suzanne Jones, PharmD, John Kuhn, PharmD, Hari P. Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Ian Flinn

Blood (2014) 124 (21): 1984.

https://doi.org/10.1182/blood.V124.21.1984.1984

Published: 2014

Journal Articles

Dual PI3Kδ/γ Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells

Swaroop Vakkalanka, PhD, Srikant Viswanadha, Ph.D., Eugenio Gaudio, PhD, Emanuele Zucca, MD, Francesco Bertoni, MD, Elena Bernasconi, B.Sc., Davide Rossi, MD, Ph.D., Anastasios Stathis, MD

Blood (2013) 122 (21): 4411.

https://doi.org/10.1182/blood.V122.21.4411.4411

Published: 2013

Journal Articles

RP6530, a Dual PI3Kδ/γ Inhibitor, Attenutates AKT Phosphorylation and Induces Apoptosis In Primary Cutaneous T Cell Lymphoma (CTCL) Cells

Julia Lewis, Ph.D, Michael Girardi, MD, FAAD, Swaroop Vakkalanka, PhD, Srikant Viswanadha, Ph.D., Francesco Bertoni, MD

Blood (2013) 122 (21): 4418.

https://doi.org/10.1182/blood.V122.21.4418.4418

Published: 2013

Journal Articles

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells

Changchun Deng, M.D, PH.D., Christine McIntosh, Richard Rodriguez, B.S., Peter Sportelli, Hari P. Miskin, MS, Swaroop Vakkalanka, PhD, Srikant Viswanadha, Ph.D., Mark Lipstein, B.S., Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 4421.

https://doi.org/10.1182/blood.V122.21.4421.4421

Published: 2013

Journal Articles

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Michael Savona, MD, Martin Gutierrez, MD, Mark Lanasa, MD, PhD, Changchun Deng, MD, PhD, John Kuhn, PharmD, Lauren Sade, Hari Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Manish Patel, MD

Blood (2013) 122 (21): 4373.

https://doi.org/10.1182/blood.V122.21.4373.4373

Published: 2013

NARROW

Treatment of Hodgkin Lymphoma Xenografts with the Novel PI3K δ/γ Inhibitor RP6530 Suppresses M2 Macrophage Polarization and Results in Potent Antitumor and Antiangiogenic Effects

TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma

A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis

The PI3K-δ Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts

Addition of RP6530, a Dual PI3Kδ/γ Inhibitor, Overcomes Ibrutinib Resistance in DLBCL Cells in Vitro

A Phase I Dose Escalation Study of RP6530, a Novel, Dual PI3K-γδ Inhibitor, for Patients with Relapsed or Refractory Hematologic Malignancies

Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma

TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma

Dual PI3Kδ/γ Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells

RP6530, a Dual PI3Kδ/γ Inhibitor, Attenutates AKT Phosphorylation and Induces Apoptosis In Primary Cutaneous T Cell Lymphoma (CTCL) Cells

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only